CN118695864A - 用于治疗化脓性汗腺炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺 - Google Patents

用于治疗化脓性汗腺炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺 Download PDF

Info

Publication number
CN118695864A
CN118695864A CN202380021843.7A CN202380021843A CN118695864A CN 118695864 A CN118695864 A CN 118695864A CN 202380021843 A CN202380021843 A CN 202380021843A CN 118695864 A CN118695864 A CN 118695864A
Authority
CN
China
Prior art keywords
subject
administration period
months
biological sample
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380021843.7A
Other languages
English (en)
Chinese (zh)
Inventor
A·特珀
A·麦斯
M·维加拉
C·拉米雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insmed Inc
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of CN118695864A publication Critical patent/CN118695864A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202380021843.7A 2022-02-16 2023-02-16 用于治疗化脓性汗腺炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺 Pending CN118695864A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263310751P 2022-02-16 2022-02-16
US63/310,751 2022-02-16
PCT/US2023/062731 WO2023159120A1 (en) 2022-02-16 2023-02-16 Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

Publications (1)

Publication Number Publication Date
CN118695864A true CN118695864A (zh) 2024-09-24

Family

ID=87579133

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380021843.7A Pending CN118695864A (zh) 2022-02-16 2023-02-16 用于治疗化脓性汗腺炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺

Country Status (11)

Country Link
US (1) US20250144116A1 (cg-RX-API-DMAC7.html)
EP (1) EP4479059A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025508359A (cg-RX-API-DMAC7.html)
KR (1) KR20240148350A (cg-RX-API-DMAC7.html)
CN (1) CN118695864A (cg-RX-API-DMAC7.html)
AU (1) AU2023221393A1 (cg-RX-API-DMAC7.html)
CA (1) CA3244131A1 (cg-RX-API-DMAC7.html)
GB (1) GB2630719A (cg-RX-API-DMAC7.html)
IL (1) IL314769A (cg-RX-API-DMAC7.html)
MX (1) MX2024009995A (cg-RX-API-DMAC7.html)
WO (1) WO2023159120A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (cg-RX-API-DMAC7.html) 2014-01-24 2018-02-24
PT3758708T (pt) 2018-03-01 2025-02-13 Astrazeneca Ab Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (cg-RX-API-DMAC7.html) * 2014-01-24 2018-02-24
WO2018022978A1 (en) * 2016-07-29 2018-02-01 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis
EP3749326A4 (en) * 2018-02-07 2021-11-03 Insmed Incorporated CERTAIN (2S) -N - [(1S) -1-CYANO-2-PHENYLETHYL] -1,4-OXAZEPAN-2-CARBOXAMIDE FOR THE TREATMENT OF VASCULITIDES ASSOCIATED WITH ANCA
EP4252844A3 (en) * 2019-04-17 2023-12-06 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
WO2024026433A2 (en) * 2022-07-28 2024-02-01 Insmed Incorporated Novel dpp1 inhibitors and uses thereof

Also Published As

Publication number Publication date
CA3244131A1 (en) 2023-08-24
EP4479059A4 (en) 2026-01-28
GB202412566D0 (en) 2024-10-09
WO2023159120A1 (en) 2023-08-24
AU2023221393A1 (en) 2024-08-15
KR20240148350A (ko) 2024-10-11
JP2025508359A (ja) 2025-03-26
MX2024009995A (es) 2024-08-22
US20250144116A1 (en) 2025-05-08
GB2630719A (en) 2024-12-04
EP4479059A1 (en) 2024-12-25
IL314769A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
JP5749255B2 (ja) L−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
US20250144116A1 (en) Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa
US20250049813A1 (en) Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
CN106999593A (zh) 用于纤维化治疗的赛尼克韦罗组合疗法
US10806735B2 (en) Use of neutrophil elastase inhibitors in liver disease
US20230338367A1 (en) Treatment of prurigo nodularis
AU2022245186A1 (en) Treatment of hidradenitis suppurativa with orismilast
JP2024133735A (ja) Iv型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
JP2016503803A (ja) 酢酸グラチラマーの経粘膜送達
JP2026069500A (ja) 線維症を治療するためのシクロスポリン類似体の使用
US20260069578A1 (en) Treatment of neutrophilic dermatoses
TW202400146A (zh) 美羅培南與法硼巴坦的組合之用途
WO2020014342A1 (en) Treatment of the pruritic symptoms of liver disease
TW202102229A (zh) 用奧貝膽酸診斷及治療肝病之方法
JP2022515615A (ja) 慢性炎症性腸疾患の治療のためのpar-1アンタゴニストの使用
US20240122956A1 (en) Application of Naringin Combined with Rapamycin in Preparation of Medications for Treating Hyperlipidemia
JPWO2005063253A1 (ja) アレルギー症状治療用医薬組成物
WO2025078838A1 (en) Alvelestat and alpha- 1 antitrypsin for treating respiratory disorders
TWI590825B (zh) 治療癌症的基於硫□酮之自體吞噬抑制劑治療
CN118369098A (zh) 用于治疗进行性纤维化间质性肺病的新颖治疗组合
HK40003409A (en) Treatment of prurigo nodularis
JP2004331661A (ja) 医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination